|
WO2020177658A1
|
|
Method for preparing tricyclic compound, and intermediate thereof
|
|
WO2019154412A1
|
|
Compound acting as antibiotics
|
|
CR20190203A
|
|
Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
|
|
US2019241515A1
|
|
Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof
|
|
CN105732615A
|
|
CDK kinase inhibitor
|
|
CN106581680A
|
|
Pharmaceutical composition for lowering food influences on drug absorption
|
|
CN105524008A
|
|
Preparation method of oxazolidinone antimicrobial drug intermediate
|
|
CN105461714A
|
|
Ring-fused PI3K inhibitors
|
|
CN105982900A
|
|
Use of purine compound in treatment or prevention of hyperuricemic or gouty diseases
|
|
CN104876914A
|
|
Pyrimidine derivative type anaplastic lymphoma kinase inhibitor
|
|
CN104804016A
|
|
Tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor
|
|
CN105732605A
|
|
Preparation method of isavuconazole intermediate
|
|
CN105524045A
|
|
Tetracyclic anaplastic lymphoma kinase inhibitor
|
|
CN104513213A
|
|
Fxr agonist
|
|
CN104418820A
|
|
Carboxylic acid derivative as lysophosphatidic acid receptor antagonist
|
|
CN104341437A
|
|
SYK inhibitor containing bicyclo-radical
|
|
CN104230960A
|
|
Four-ring anaplastic lymphoma kinase inhibitor
|
|
CN104098563A
|
|
JNK (stress-activated kinases,SAPK) inhibitor compound
|
|
CN104788412A
|
|
Aromatic polycyclic carboxylic acid derivatives
|
|
CN104250239A
|
|
Aromatic polycyclic carboxylic acid derivative
|
